Download PDF
Aktuelle Urol 2025; 56(02): 158-163
DOI: 10.1055/a-2552-1170
Originalarbeit

Geschlechtsspezifische Unterschiede urologischer Tumore

Gender-specific differences in urological tumours
Julia Weiss 
1   Department of Urology, Medical University of Vienna, Wien, Austria (Ringgold ID: RIN27271)
,
Ekaterina Laukhtina
1   Department of Urology, Medical University of Vienna, Wien, Austria (Ringgold ID: RIN27271)
,
Irene Resch
1   Department of Urology, Medical University of Vienna, Wien, Austria (Ringgold ID: RIN27271)
,
Shahrokh F. Shariat
1   Department of Urology, Medical University of Vienna, Wien, Austria (Ringgold ID: RIN27271)
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Geschlechtsunterschiede in der Medizin spielen mittlerweile eine nicht mehr wegzudenkende Rolle, sowohl in Diagnostik als auch Therapie. Risikofaktoren und Mortalität variieren je nach Geschlecht, Krankheiten äußern sich unterschiedlich. In der Diagnostik müssen je nach Geschlecht unterschiedliche Aspekte in Betracht gezogen werden. Bei Blasenkarzinomen zum Beispiel kommt es bei Frauen häufig zu Verzögerungen bei der Diagnose, weil Hämaturie oft benignen Erkrankungen wie Harnwegsinfekten zugeschrieben wird.
Bei Therapieentscheidungen sollte das Geschlecht ebenso eine Rolle spielen. Um ein Beispiel zu nennen, haben Immuncheckpoint-Inhibitoren bei Nierenzellkarzinomen bei Männern ein besseres Ansprechen als bei Frauen. Auch die Outcomes nach onkologischer Therapie bei urologischen Tumoren variieren nach Geschlecht.

Abstract

Gender differences in medicine are playing an increasingly important role in diagnostic testing as well as therapy choices. Risk factors and mortality vary depending on gender. Diseases often manifest differently depending on gender. In diagnostic testing, gender-specific aspects need to be taken into consideration. For instance, bladder cancer diagnosis is often delayed in women compared to men as haematuria is frequently attributed to benign conditions like urinary tract infections. In therapy, decisive gender disparities should also be considered. To state an example, immune-checkpoint inhibitors have shown better response in men than in women when treating renal cell carcinoma. Furthermore, outcomes after treatment for urological tumours differ depending on gender.

Schlüsselwörter

Geschlechtsunterschiede - Urologische Tumore - Urothelkarzinom

Keywords

Gender Differences - Urological Tumors - Urothelial Cancer


Publication History

Received: 05 November 2024

Accepted after revision: 04 March 2025

Article published online:
03 April 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Bray F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424
    CrossrefPubMedSearch in Google Scholar
  • 2 Burger M. et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013; 63: 234-41
    CrossrefPubMedSearch in Google Scholar
  • 3 Pallauf M. et al. A Systematic Review and Meta-Analysis of Prognostic Nomograms After UTUC Surgery. Front Oncol 2022; 12
    CrossrefPubMedSearch in Google Scholar
  • 4 Sung H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209-249
    CrossrefPubMedSearch in Google Scholar
  • 5 WHO. International Agency for Research on Cancer. Cancer tomorrow. 2023 https://gco.iarc.fr/tomorrow/en
    CrossrefPubMedSearch in Google Scholar
  • 6 Jemal A. et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96
    CrossrefPubMedSearch in Google Scholar
  • 7 Ferlay J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-E386
    CrossrefPubMedSearch in Google Scholar
  • 8 Waldhoer T. et al. Sex Differences of ≥ pT1 Bladder Cancer Survival in Austria: A Descriptive, Long-Term, Nation-Wide Analysis Based on 27,773 Patients. Urol Int 2015; 94: 383-389
    CrossrefPubMedSearch in Google Scholar
  • 9 Antoni S. et al. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol 2017; 71: 96-108
    CrossrefPubMedSearch in Google Scholar
  • 10 Radkiewicz C. et al. Sex Differences in Urothelial Bladder Cancer Survival. Clin Genitourin Cancer 2020; 18: 26-34.e6
    PubMedSearch in Google Scholar
  • 11 Torre LA. et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108
    CrossrefPubMedSearch in Google Scholar
  • 12 Scosyrev E. et al. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer 2009; 115: 68-74
    CrossrefPubMedSearch in Google Scholar
  • 13 Fajkovic H. et al. Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol 2011; 29: 457-463
    CrossrefPubMedSearch in Google Scholar
  • 14 Kluth LA. et al. Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients. Eur Urol 2014; 66: 913-919
    PubMedSearch in Google Scholar
  • 15 Lucca I. et al. Gender differences in incidence and outcomes of urothelial and kidney cancer. Nat Rev Urol 2015; 12: 585-592
    CrossrefPubMedSearch in Google Scholar
  • 16 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7-30
    CrossrefPubMedSearch in Google Scholar
  • 17 Poli C. et al. Sex differences in muscle-invasive bladder cancers: a study of a French regional population. Fr J Urol 2024; 35
    CrossrefPubMedSearch in Google Scholar
  • 18 Palou J. et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol 2012; 62: 118-125
    PubMedSearch in Google Scholar
  • 19 Fernandez-Gomez J. et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008; 53: 992-1001
    PubMedSearch in Google Scholar
  • 20 Mungan NA. et al. Gender differences in stage distribution of bladder cancer. Urology 2000; 55: 368-371
    CrossrefPubMedSearch in Google Scholar
  • 21 Freedman ND. et al. Association between smoking and risk of bladder cancer among men and women. JAMA 2011; 306: 737-745
    CrossrefPubMedSearch in Google Scholar
  • 22 Kuper H, Boffetta P, Adami HO. Tobacco use and cancer causation: association by tumour type. J Intern Med 2002; 252: 206-224
    CrossrefPubMedSearch in Google Scholar
  • 23 Volanis D. et al. Environmental factors and genetic susceptibility promote urinary bladder cancer. Toxicol Lett 2010; 193: 131-137
    CrossrefPubMedSearch in Google Scholar
  • 24 Stewart SL. et al. Surveillance for cancers associated with tobacco use--United States 1999–2004. MMWR Surveill Summ 2008; 57: 1-33
    PubMedSearch in Google Scholar
  • 25 Strope SA, Montie JE. The causal role of cigarette smoking in bladder cancer initiation and progression, and the role of urologists in smoking cessation. J Urol 2008; 180: 31-37
    CrossrefPubMedSearch in Google Scholar
  • 26 Jacob L. et al. Impact of tobacco smoking on the risk of developing 25 different cancers in the UK: a retrospective study of 422,010 patients followed for up to 30 years. Oncotarget 2018; 9: 17420-17429
    CrossrefPubMedSearch in Google Scholar
  • 27 Ide H, Inoue S, Miyamoto H. Histopathological and prognostic significance of the expression of sex hormone receptors in bladder cancer: A meta-analysis of immunohistochemical studies. PLoS One 2017; 12
    CrossrefPubMedSearch in Google Scholar
  • 28 Dobruch J. et al. Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. Eur Urol 2016; 69: 300-310
    CrossrefPubMedSearch in Google Scholar
  • 29 Mori K. et al. Impact of sex on outcomes after surgery for non-muscle-invasive and muscle-invasive bladder urothelial carcinoma: a systematic review and meta-analysis. World J Urol 2023; 41: 909-919
    CrossrefPubMedSearch in Google Scholar
  • 30 Martin-Doyle W. et al. Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients. J Clin Oncol 2015; 33: 643-650
    CrossrefPubMedSearch in Google Scholar
  • 31 Uhlig A. et al. Gender-specific Differences in Recurrence of Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus 2018; 4: 924-936
    CrossrefPubMedSearch in Google Scholar
  • 32 Kluth LA. et al. Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. World J Urol 2013; 31: 1029-1036
    PubMedSearch in Google Scholar
  • 33 D'Andrea D. et al. Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer. World J Urol 2021; 39: 3337-3344
    PubMedSearch in Google Scholar
  • 34 Shang Z. et al. Targeting estrogen/estrogen receptor alpha enhances Bacillus Calmette-Guérin efficacy in bladder cancer. Oncotarget 2016; 7: 27325-27335
    CrossrefPubMedSearch in Google Scholar
  • 35 May M. et al. Gender-dependent cancer-specific survival following radical cystectomy. World J Urol 2012; 30: 707-713
    CrossrefPubMedSearch in Google Scholar
  • 36 Messer JC. et al. Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. Urology 2014; 83: 863-867
    PubMedSearch in Google Scholar
  • 37 Zietman AL. et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol 2003; 170: 1772-1776
    CrossrefPubMedSearch in Google Scholar
  • 38 Philipps L. et al. Differences in Quality of Life and Toxicity for Male and Female Patients following Chemo(radiotherapy) for Bladder Cancer. Clin Oncol (R Coll Radiol) 2023; 35: e336-e343
    CrossrefPubMedSearch in Google Scholar
  • 39 Witjes JA. et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol 2017; 71: 462-475
    PubMedSearch in Google Scholar
  • 40 Zargar H. et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2015; 67: 241-249
    CrossrefPubMedSearch in Google Scholar
  • 41 Rose TL. et al. Sex disparities in use of chemotherapy and survival in patients with advanced bladder cancer. Cancer 2016; 122: 2012-2020
    PubMedSearch in Google Scholar
  • 42 Konety BR, Joslyn SA. Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program. J Urol 2003; 170: 1765-1771
    CrossrefPubMedSearch in Google Scholar
  • 43 Krimphove MJ. et al. Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. Eur Urol Focus 2021; 7: 124-131
    PubMedSearch in Google Scholar
  • 44 Uhlig A. et al. Gender Specific Differences in Disease-Free, Cancer Specific and Overall Survival after Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis. J Urol 2018; 200: 48-60
    PubMedSearch in Google Scholar
  • 45 D'Andrea D. et al. Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. Urol Oncol 2020; 38: 639.e1-639.e9
    PubMedSearch in Google Scholar
  • 46 Cerrato C. et al. Effect of Sex on the Oncological Outcomes in Response to Immunotherapy and Antibody-drug Conjugates in Patients with Urothelial and Kidney Cancer: A Systematic Review and a Network Meta-analysis. Eur Urol Oncol 2024; 7: 1005-1014
    PubMedSearch in Google Scholar
  • 47 Yanagisawa T. et al. Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis. World J Urol 2023; 41: 1763-1774
    CrossrefPubMedSearch in Google Scholar
  • 48 Farber NJ. et al. Disparities in the Use of Continent Urinary Diversions after Radical Cystectomy for Bladder Cancer. Bladder Cancer 2018; 4: 113-120
    CrossrefPubMedSearch in Google Scholar
  • 49 von Deimling M. et al. Radical cystectomy and urinary diversion in women: techniques, outcomes, and challenges-a narrative review. Transl Androl Urol 2022; 11: 1598-1610
    PubMedSearch in Google Scholar
  • 50 Groeben C. et al. Urinary Diversion After Radical Cystectomy for Bladder Cancer: Comparing Trends in the US and Germany from 2006 to 2014. Ann Surg Oncol 2018; 25: 3502-3509
    PubMedSearch in Google Scholar
  • 51 Bhatt A. et al. Neurovascular preservation in orthotopic cystectomy: impact on female sexual function. Urology 2006; 67: 742-745
    CrossrefPubMedSearch in Google Scholar
  • 52 Zippe CD. et al. Female sexual dysfunction after radical cystectomy: a new outcome measure. Urology 2004; 63: 1153-1157
    CrossrefPubMedSearch in Google Scholar
  • 53 Anderson CB. et al. Voiding function in women with orthotopic neobladder urinary diversion. J Urol 2012; 188: 200-204
    PubMedSearch in Google Scholar
  • 54 Finley DS. et al. Urinary retention after orthotopic neobladder substitution in females. J Urol 2011; 186: 1364-1369
    CrossrefPubMedSearch in Google Scholar
  • 55 Singla N. et al. A Multi-Institutional Comparison of Clinicopathological Characteristics and Oncologic Outcomes of Upper Tract Urothelial Carcinoma in China and the United States. J Urol 2017; 197: 1208-1213
    CrossrefPubMedSearch in Google Scholar
  • 56 Mori K. et al. Differential Effect of Sex on Outcomes after Radical Surgery for Upper Tract and Bladder Urothelial Carcinoma: A Systematic Review and Meta-Analysis. J Urol 2020; 204: 58-62
    CrossrefPubMedSearch in Google Scholar
  • 57 Zimmermann K. et al. Health-related quality of life in bladder cancer patients: general and cancer-specific instruments. Part 1. Curr Opin Urol 2021; 31: 297-303
    CrossrefPubMedSearch in Google Scholar
  • 58 Catto JWF. et al. Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes. Eur Urol 2021; 79: 621-632
    CrossrefPubMedSearch in Google Scholar
  • 59 Grobet-Jeandin E. et al. Health-related quality of life after curative treatment for muscle-invasive bladder cancer. Nat Rev Urol 2023; 20: 279-293
    CrossrefPubMedSearch in Google Scholar